Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)

Opal Center是根据其优化和个性化干预措施的目标命名的 终生精神分裂症。该快感中心的目标人群是被诊断为 精神分裂症，通常影响个人从青春期或成年早期到生命末期。 受影响的个人通常有社会和职业功能受损； 精神病和情绪症状；有可能进展的认知问题；有残疾和 过早死亡。黑人、土著和有色人种(BIPOC)个人尤其面临贫困的风险 结果。本次续展申请的目标是扩大我们的努力，以加快发展和 在真实的临床环境中实施有效的、个性化的精神分裂症治疗。 中心续签申请的具体目的如下： 1.加强我们的基础设施，支持研究创新的优化方法 对精神分裂症患者的终生治疗，加速了临床 对精神分裂症患者进行常规训练的研究。 2.开展开发、调整和测试创新性、可获得性和以人为中心的干预措施的项目 可提高治疗参与度，并可随时部署。 3.培训科学家，他们将对精神分裂症的干预进行转化研究。 Opal签名项目将使用来自医疗补助和医疗补助中心的16年(2007-2022)数据 医疗保险服务(CMS)测试诊断为痴呆症的人中有关痴呆症风险因素的假设 并比较精神分裂症患者诊断为痴呆症后治疗策略的疗效。到时候我们会的 整合我们的发现，以适应提供评估和管理工具的认知健康工具包。 探索性项目1测试了一种新的、以人为中心的评估和治疗启动方法 对于在社区精神卫生诊所有精神病症状的BIPOC个人，该诊所纳入了 文化制定访谈的改编版本，以提高诊断和治疗参与度。 探索性项目2将建立在欧洲工作的基础上，以适应和测试可行性和 灵活自信社区治疗(ACT)的初步有效性，这将使ACT团队能够 根据参与者的个人需求分配资源，提高效率和成果。 探索性项目3使用移动医疗(MHealth)技术提供基于测量的医疗服务 并改善精神分裂症患者一生中以人为中心的结果。 Opal项目使用中心的共同资源和方法来改进执行和 针对重要问题的个性化治疗。利益相关者帮助我们改进和调整干预措施 在现实世界环境中有效实施。

The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life. Affected individuals commonly have impaired social and occupational functioning; experience persistent psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and implementation of effective, individualized treatments for schizophrenia in real clinical settings. The specific aims of the Center renewal application are as follows: 1. Strengthen our infrastructure that supports research that examines innovative ways to optimize treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical research on schizophrenia to routine practice settings. 2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions that improve engagement in treatment and can be readily deployed. 3. Train scientists who will conduct translational research on interventions for schizophrenia. The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools. Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement. Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to allocate resources according to the individual needs of participants, improving efficiency and outcomes. Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care and improve the person-centered outcomes of individuals with schizophrenia across the lifespan. OPAL projects use the Center's common resources and methodologies to improve implementation and personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for effective implementation in real-world settings.